SAN DIEGO–(BUSINESS WIRE)– #CellRegeneration–Stemson Therapeutics announced today the closing of a DCVC Bio-led $15 million Series A financing to advance development of Stemson’s proprietary therapeutic solution to cure hair loss. Genoa Ventures, AbbVie Ventures and other investors join in supporting Stemson’s efforts to restore human hair growth with a novel cell regeneration technology using the patient’s own cells to generate new hair follicles. In addition, Kiersten Stead, Ph.D., Co-Managing Partner at DCVC
Click here to view original post